AnPac Bio-Medical Science, which provides multi-cancer screening tests in China, filed on Thursday with the SEC to raise up to $22 million in an initial public offering.
The Lishui, China-based company was founded in 2008 and booked $1.6 million in revenue for the 12 months ended June 30, 2019. It plans to list on the Nasdaq under the symbol ANPC. AnPac Bio-Medical Science filed confidentially on September 20, 2019. WestPark Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
